Morphic to Participate in March Investor Conferences
Morphic Therapeutic (MORF) announces participation in investor conferences, including panels and fireside chats, during March 2024. The company focuses on developing oral integrin therapies for chronic diseases.
03/05/2024 - 04:05 PM
WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March.
3/6/24 th Annual Health Care Conference
10:30 AM ETth Annual Health Care Conference
3/13/24
A live webcast of the panel discussion and fireside chat at the TD Cowen 44th Annual Health Care Conference will be available on the Investor section of Morphic’s website at www.morphictx.com . An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic www.morphictx.com .
Contacts chris.erdman@morphictx.com
When is Morphic Therapeutic (MORF) participating in investor conferences in March 2024?
Morphic Therapeutic (MORF) is participating in investor conferences during the month of March 2024.
What type of therapies does Morphic Therapeutic (MORF) focus on developing?
Morphic Therapeutic (MORF) focuses on developing a new generation of oral integrin therapies for serious chronic diseases.
Where can I watch the panel discussion and fireside chat at the TD Cowen 44th Annual Health Care Conference?
You can watch the panel discussion and fireside chat at the TD Cowen 44th Annual Health Care Conference on the Investor section of Morphic’s website at www.morphictx.com.
MORF Rankings
#3755 Ranked by Stock Gains
MORF Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Waltham
About MORF
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
